Get the Stockscreener App
5.49
1.61%
-0.09
After Hours:
5.42
-0.07
-1.28%
Xeris Biopharma Holdings Inc stock is traded at $5.49, with a volume of 5.87M.
It is down -1.61% in the last 24 hours and up +43.34% over the past month.
See More
Previous Close:
$5.58
Open:
$5.48
24h Volume:
5.87M
Relative Volume:
2.45
Market Cap:
$903.63M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-13.07
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
-6.47%
1M Performance:
+43.34%
6M Performance:
+92.63%
1Y Performance:
+148.42%
1-Day Range:
$5.29
$5.585
1-Week Range:
$5.29
$6.07
52-Week Range:
$1.69
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.49 | 903.63M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi - openPR
Xeris Pharmaceuticals Announces Board Changes with New Appointment - TipRanks
Xeris Announces Changes To Its Board Of Directors - MarketScreener
Xeris Biopharma reshuffles board, appoints new director - Investing.com
Xeris Biopharma reshuffles board, appoints new director By Investing.com - Investing.com Australia
Ex-AstraZeneca CFO Joins Xeris Board: Strategic Move Adds 30 Years Pharma Expertise - Stock Titan
Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? - Insider Monkey
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Bank of New York Mellon Corp - Defense World
Don't Ignore The Insider Selling In Xeris Biopharma Holdings - simplywall.st
Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (NASDAQ:XERS) Stock Price Up 4.9% – Here’s Why - Defense World
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock - Investing.com Australia
Xeris Biopharma chief legal officer Beth Hecht sells $217,244 in stock By Investing.com - Investing.com South Africa
Xeris Pharmaceuticals stock hits 52-week high at $5.54 - Investing.com
Xeris Pharmaceuticals stock hits 52-week high at $5.54 By Investing.com - Investing.com South Africa
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Reaches New 52-Week High – Time to Buy? - Defense World
Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris enters a whole new market for one of its main pharma offerings - Crain's Chicago Business
Is XERS Stock a Good Buy in 2025? Key Insights for Investors - Stocks Telegraph
12 Best Stocks to Invest in for a Stock Market Game - Insider Monkey
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent - Investing.com Australia
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid - BioSpace
Xeris Biopharma Says US FDA Approves Gvoke VialDx for Diagnostic Use -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Xeris Biopharma gets FDA nod for Gvoke VialDx, teams with American Regent By Investing.com - Investing.com South Africa
Breakthrough FDA Approval: Xeris' Novel Glucagon Solution Transforms Radiologic Diagnostics - Stock Titan
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator (NASDAQ:XERS) - Seeking Alpha
Investors Appear Satisfied With Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Prospects As Shares Rocket 34% - Simply Wall St
Xeris BiopharmaPossibly the best Pharma Stock - MSN
Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Target Price at $5.92 - Defense World
Will Xeris Biopharma's Financial Transformation Reach New Heights In 2025? - RTTNews
Xeris Biopharma (XERS) Expects to Ride the Wave of 30% Revenue Growth in 2025 - Markets Insider
What Are Expectations For Xeris Biopharma Holdings Inc (NASDAQ: XERS) In The Short Term? - Stocks Register
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript - Insider Monkey
Analysts Issue Forecasts for Xeris Biopharma Q1 Earnings - Defense World
Piper Sandler Reaffirms Neutral Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS) - Defense World
Who Really Controls Xeris Biopharma? The Retail Investors’ Unseen Power - DSA
Principal Financial Group Inc. Grows Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Rhumbline Advisers Purchases 7,408 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highli - GuruFocus.com
Xeris Biopharma Reports Record Revenue and Strong 2025 Outlook - TipRanks
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In - MSN
Xeris Biopharma Holdings Inc. (XERS) reports earnings - Quartz
Xeris Biopharma Holdings, Inc. SEC 10-K Report - TradingView
Xeris Biopharma: Q4 Earnings Snapshot - CT Insider
Navigating XERS Stock: Xeris Biopharma Holdings Inc Journey - The InvestChronicle
Earnings call transcript: Xeris Pharmaceuticals Q4 2024 beats EPS forecast, stock surges By Investing.com - Investing.com South Africa
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance - BioSpace
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):